The aim was to explore the regulatory effect of SSRI drugs on VGLUT2 in the prefrontal cortex and its impact on the behavioral and histopathological changes in rats with depression-induced cognitive dysfunction, providing more insights for the clinical treatment of cognitive dysfunction caused by depression. Here, SLC17A6 is linked to major depressive disorder.